A review of clinical and histological parameters associated with contralateral neck metastases in oral squamous cell carcinoma

Song Fan†, Qiong-lan Tang†, Ying-jin Lin†, Wei-liang Chen*, Jin-song Li, Zhi-quan Huang, You-yuan Wang, Da-ming Zhang, Hui-jing Wang, Eduardo Dias-Ribeiro, Qiang Cai, Lei Wang

†These authors contributed equally to this work.

*Correspondence: Wei-liang Chen
Tel: 86 20 81332429; Fax: 86 20 81332853
E-mail: drchen@vip.163.com

Received 14 March 2011; Accepted 23 August 2011

Introduction

Oral squamous cell carcinoma (OSCC) is the most frequent of head and neck malignancies, which represents approximately 3% of all malignancies in the body and accounts for more than five hundred thousand newly diagnosed cancers every year worldwide. Several studies have been concerned on the cervical metastases and prognosis of OSCC. Recently, more retrospective studies have analysed some clinical-histopathologic prognosticators influencing contralateral neck metastases (CLNM) in OSCC. OSCC has a high incidence of cervical micrometastases and sometimes metastasizes contralaterally because of the rich lymphatic intercommunications relative to submucosal plexus of oral cavity that freely communicate across the midline [1]. It is widely accepted that the presence of lymph node metastases is one of the most important prognosticators related to survival of OSCC, and several studies have shown this influence by the drastic decrease in survival rates in patients with positive neck nodes [2-6], with most succumbing to
locoregional recurrence. Therefore, cervical metastases remain a topic of interest for oral surgeons [3-4]. This review details clinical-histopathologic factors for CLNM, and considers their relative merits and disadvantages, and also summarizes the indications for elective contralateral neck dissection and adjuvant treatment, timing of CLNM occurrence and strategies for follow-up.

Incidence of CLNM in OSCC

CLNM in OSCC involved complex mechanism and anatomic structures of the cervical region, while numerous biological and molecular factors may be considered. However, the exact mechanism that takes place in contralateral metastases is not yet clear. Some authors recognize that contralateral metastases of head and neck carcinomas can occur in different ways: firstly, by crossing afferent lymph vessels; and second by tumor spreading over the midline to reach efferent collateral lymphatic vessels while ipsilateral lymph nodes are extensively involved, where there is not a real midline barrier in certain anatomic areas [7]. The incidence of CLNM differs considerably among institutions from 0.9% to 36% [6, 8-21].

Diagnosis

The most important prognostic factor for tumor behavior and outcome in squamous cell carcinoma (SCC) of the oral cavity is the presence and extent of cervical lymph node metastases at initial diagnosis. The basic procedure to check cervical lymph node is physical examination, but clinical examination alone is not enough to establish the true extent of local involvement and regional metastases [22]. Therefore, auxiliary modern diagnostic modalities, such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), lymphoscintigraphy (LS), and ultrasonography (USG) and USG-guided fine needle aspiration cytology, are recommended to increase the efficacy of the neck evaluation in patients with oral carcinoma, and some having become routine screening procedures in recent years [23]. LS can supply a complete map of the lymphatic drainage preoperatively and serve to guide lymphadenectomy, making it possible to tailor selective neck dissection and reducing surgery related morbidity [24]. PET is a promising imaging tool, but its sensitivity is still insufficient for it to replace surgical lymph node staging [25].

Clinicians should especially emphasize the importance of the clinical N0 neck, which is defined as having no cervical lymph nodes palpated on physical examination and no findings on imaging studies that correlate with Mancuso’s criteria [26] for benign nodes. However, there are limitations of all these imaging modalities for the detection of very small micrometastases within these nonpalpable neck nodes [23]. Metastases may unfortunately not be visible in some small positive lymph nodes by conventional imaging techniques. The researchers [27] demonstrated that approximately 25% of all clinically occult metastases are too small to be detected using any of the available imaging techniques. Lin et al. [28] also found that discrepancies between clinical and pathologic staging were not uncommon, with a difference of 43.4% for N stage and 29.7% for T stage. Approximately two thirds of patients were clinically over-staged for T, while two thirds were under-staged for N.

Prognosis

It has been widely accepted that contralateral neck lymph nodes are strongly correlated with poor prognosis, positive contralateral metastases significantly reducing long-term survival in several studies [3-4, 6, 8, 13-14, 29-32]. Capote-Moreno et al. [6] found a statistical influence of contralateral lymph node metastases on survival in a study of 402 patients of oral and oropharyngeal SCC. Patients with positive contralateral metastases showed a decrease in survival rate, with a 5-year cause-specific survival rate of 41.2% versus 70% in the group with negative contralateral metastases. Similarly, Koo et al. [29] observed a 5-year cause-specific survival rate of 43% in patients with contralateral disease compared with 73% in metastasis-free patients in a series of 173 cases with oral and oropharyngeal SCC. In a series of 1 069 cases in whom cervical dissection was performed for the treatment of oral and oropharyngeal carcinoma, Spiro et al. [30] reported that the five-year survival rate in patients with ipsilateral nodal metastasis was 28%, but this rate decreased significantly to 8% in cases of bilateral metastasis. It is obviously that the prognosis of patients with CLNM in OSCC remains poor.

Clinical-histopathologic factors

In relation to primary OSCC, many clinical and histopathologic factors have been reported to be predictive for CLNM recently. Efforts have been made to elucidate tumor-related factors that could influence the appearance of CLNM in OSCC.

Tumor location

Tumor location has been speculated as a determinant
factor for CLNM in several previous reports: although, there is not a clear consensus about which location is of higher risk for contralateral metastases. Traditionally, SCC of the oral cavity located in the midline has been associated with an increase in bilateral or contralateral cervical lymph node metastasis [10, 18]. Therefore, tumors arising in the region between both canines have been excluded in several studies recently in order to determine the relationship between primary tumor features and the appearance of CLNM.

Interestingly, OSCC extending the midline have been related to the most important predictors of contralateral or bilateral metastases on multivariate logistic regression analysis [6, 8, 11, 13], due to the involvement of the contralateral lymphatic drainage. In 1951, Martin et al. [10] reported that primary tumor invasion crossing the midline of oral cavity was associated with a higher incidence of contralateral metastases. Sixteen percent of the tumors crossing the midline less than 1 cm developed CLNM, but this value increased to 46% in cases that invaded the midline greater than 1 cm. Koo et al. [29] also demonstrated the rate of contralateral occult neck metastasis was significantly higher in cases in which the primary lesion showed extension across the midline, compared with early-stage or unilateral lesions. In a series including 513 consecutive cases, Kowalski et al. [8] testified that the risks of contralateral metastases were significantly higher in cases of tumors extending to 1 cm or less of the midline or crossing such medial margin (relative risk from 2.8 to 12.7).

When the primary site is considered, the incidence of CLNM varies broadly in the oral cavity. Capote-Moreno et al. [6] observed a higher tendency for contralateral metastases in tumors located in the tongue base (31.4%) and the floor of the mouth (11%), with a lower frequency in the mobile tongue (7.2%) and the oropharynx (6.3%). Researchers [7-8, 33] have suggested that patients with primary tumor of the floor of the mouth, which is known to have a rich and bilateral lymphatic drainage pattern exhibit a higher risk of contralateral metastases than those with tongue tumors or those invading the retromolar trigone. It was also found that a higher rate of contralateral metastases in the base of the tongue, even in early tumors, than in tumors of the tonsillar fossa or the body and the tip of the tongue by Olzowy et al. [21] and Califano et al. [34]. However, diverse findings have also been reported the most-contrasting data showing a higher incidence of CLNM in cases of lower gum carcinoma (25%) in comparison with those tumors starting on the mobile tongue (15.4%) [13].

In summary, patients with tumors arising in the base of tongue and floor of the mouth have a high frequency of CLNM than those tumors associated with a significant reduction of contralateral metastases that involve the retromolar trigone area and mobile tongue.

**Tumor size**

According to TNM staging classification system, tumor size based on the greatest surface dimension—“tumor diameter”. Several studies have widely described a correlation between large size at presentation and contralateral metastases, which are associated with an increased risk of poor survival [8, 13, 21, 29, 35-39]. Risks of CLNM for cases of tumors at stage T4 and patients seen with two involved sites are significantly higher in relation to those with tumors confined to the original site or at early stage. In a retrospective analysis of 66 patients with cancer of the oral cavity at NO–2 stage, Koo et al. [29] showed that the rate of contralateral occult metastasis was 8% for T2, 25% for T3, and 18% for T4, whereas no metastasis was observed in the T1 cases. It is also noteworthy that fewer bilateral metastases were seen for T1 tumors compared with more advanced primaries [21] and the patients with bilateral metastases had at least T2 disease or greater [39].

**Tumor thickness**

Tumor thickness is determined by the vertical measurement starting from the line of the mucosa up to the maximum point of the invasion using a millimetric lens (0/20 mm) [40-42]. Both for exophytic and invasive tumors, the upper point of the measurement is the line of the mucosa [43]. Thickness is a direct micrometer measurement by the pathologist of the vertical bulk of tumor regardless of the histologic structure of the ulcerative or exophytic form of tumor growth [44]. Consequently, studies on measurement standard of tumor thickness or depth are very controversial in the literature [45-47], it is possible that the cut of the paraffin block is not exactly vertical depth.

Otherwise, tumor thickness is now recognized as a more accurate histological prognosticator of cervical nodal metastasis, local recurrence, and survival than diameter [8, 20, 42, 48-53]. Bier-Laning et al. [20] found an approximately 5% increased risk of CLNM for every 1-mm increased in tumor thickness, and there were no cases of contralateral nodal metatases when the primary tumor had a thickness <3.75 mm. Others [8, 53] have also demonstrated that risks of contralateral metastases were higher in cases of tumors with over 6 mm in relation to cases of up to 3 mm thickness and tumor thickness>4 mm were independent factors predicting for late cervical metastases in early-stage oral tongue cancer. Nevertheless, González-García et al. [18] failed to show
tumoral thickness greater than 2 mm as predictive for CLNM, which could be attributable to the insufficient sample size where 7.1% of the patients with tumor thickness greater than 2 mm developed CLNM in comparison with 0% of the patients with tumor thickness less than 2 mm.

Clinical stage

Kowalski et al. [8] reported that the clinical stage was the most important predictors of contralateral metastasis. Meanwhile, several independent studies have also shown that patients with advanced tumors are at a higher risk for contralateral lymph node metastasis in SCC of oral cavity [8, 13, 18, 29]. For example, Kowalski et al. [8] found that the risk of contralateral metastases in the 297 cases eligible for analysis, the groups of clinical stage (CS) II, III, and IV had risks from 1.8 to 9.6 times higher than the cases of CS I.

Surgical margin status

The surgical margins include both the surface mucosa at the edge of the tumor and the submucosal and deeper connective tissues all around the defect [54]. The involvement of tumor cells at surgical margins has been regarded as one of the most important prognosticators in patients with SCC of oral cavity. Many studies have suggested that complete tumor excision with an adequate margin is an important clinical procedure [55-58]. Even the relative risk of death associated with a close margin is similar to that associated with nodal metastasis [59]. In a nearly recent report, Nason et al. [60] found that the survival improved with each additional millimeter of clear surgical margin, each 1-mm increase in clear surgical margin decreased the risk of death at 5 years by 8%. On univariate correlation analysis for contralateral metastases, authors have demonstrated that surgical margins had a statistical association with a high risk of contralateral lymph node metastases developing [6, 18].

Therefore, the precise definition of the clear or adequate surgical margin is an important prognostic consideration and even determines adjuvantive treatments for certain patients with OSCC. Histological margin is considered involved when the presence of invasive carcinoma and/or carcinoma “in situ” on the margins of the mucosa is identified and/or the distance of tumor to the normal mucosa margin is less than 5 mm [6, 43]. According to UK guidelines, the status of both the mucosal and deep margins and designate margins of 5 mm or more are considered as clear, 1–5 mm as close, and less than 1 mm as involved. Woolgar [54] suggests that even 5 mm may not be “clear” when the pattern of invasion is highly unfavorable with widely separated tumor satellites. However, in a retrospective study based on a historical cohort of 277 surgically treated patients with oral cancer, Nason et al. [60] recently suggested that an inadequate or close margin was defined as tumor within 3 mm of the inked resection margin and that the widely accepted definition of a close margin as within 5 mm needs to be reassessed. Considering the shrinkage effect of surgical specimens, on the order of 40% to 50%, when fixed in formalin [61], it is generally accepted that the surgical resection margin presenting 1 cm or more of non-affected tissue around the tumor is considered adequate. Illustratively, authors reported that only 4% of patients in groups of specimens with more than 1 cm of non-affected tissue around the tumor developed CLNM in contrast to 11.6% of patients with surgical resection margin presenting less than 1 cm [18].

A clear margin has been believed to assure adequate treatment by surgery. However, this concept has recently been challenged by several studies in which pathologically document that adequate margins cannot necessarily guarantee tumor cells are removed completely [62-66] and patients with clear margins do not always have good clinical outcomes, as local recurrence rates with clear margins in tongue cancer ranged from 4% to 18% [56, 58, 62]. As a result, there is not a single definition for an adequate resection margin. Several variables, including tumor thickness, the pattern of tumor invasion, tumor satellites, tumor satellite distance, and other clinical factors should be considered.

Parameters of the cervical (regional) lymph nodes

The prognostic importance of the presence and extent of cervical lymph node metastasis in SCC of oral cavity has been recognized for many decades. Numerous independent authorities have reported an association between occurrence of CLNM and homolateral lymph node metastasis: although, there is no general agreement on which features are the best prognosticators [6-8, 10-11, 13-14, 18-19, 32, 67]. In relation to several features of cervical lymph node affection [54], the number and the level of ipsilateral lymph node metastasis has been widely investigated while extracapsular spread (ECS) has been commonly confirmed.

Patients with metastatic homolateral cervical lymph nodes have a high risk of contralateral metastases (4.8 times higher) in comparison with the cases with no metastases on the same side of the neck, as reported by Kowalski et al. [8]. Other authors [13, 21] have further demonstrated that patients with multiple ipsilateral positive nodes (two or more) presented with a higher risk for contralateral metastases or bilateral metastases than those with a single positive node or negative nodes.
For example, Kurita et al. [13] reported that the incidence of CLNM was higher in patients with multi-node involvement (50%) than in those with single node involvement (26.1%). The level of homolateral node metastasis was also correlated with CLNM. Level IV/V lymph node metastasis was an independent risk factors for the five-year rates of CLNM [19]. Interestingly, a few authors have reported that CLNM never occurred in patients without homolateral lymph node metastasis, but only simultaneously with and after homolateral neck node metastasis [13, 68], which suggests CLNM is unlikely if homolateral node metastasis has not occurred.

A possible explanation is that the performance of elective neck dissection together with primary tumor resection may predispose patients to aberrant migration of in-transit carcinomatous cells to the opposite side of the neck [68]. Therefore, the management of contralateral N0 neck in early SCC of oral cavity also may need to considered in order to prevent later cervical metastasis, according to these findings [15].

The extent of ECS is recorded as “macroscopic” and “microscopic”, when it is obvious on laboratory inspection and only evident on histological assessment, respectively [54]. The prognostic importance of ECS has also been emphasized by several studies and it is commonly recognized as a simple, sensitive and highly discriminating indicator [3, 19, 39, 54, 69-72]. In a series of 913 patients, Liao et al. [19] have shown that the five-year CLMN rate was significantly higher in patients with ECS (39%) than in those without (12%). Furthermore, the five-year OS was 48% in patients without ECS, whereas it dropped to 16% in those with ECS.

**Histological grading**

The histological grading OSCC is adopted by Broders’/WHO grading system which recommends three categories: grade 1 (well differentiated), grade 2 (moderately differentiated), and grade 3 (poorly differentiated). It mainly takes into account a subjective assessment of the degree of keratinisation, cellular and nuclear pleomorphism, and mitotic activity [73].

More and more authorities now recognize that Broders’/WHO grade alone shows poor correlation with prognosis and response to treatment in an individual patient [51-52, 73]. It is probably attributed to the lack of discrimination inherent in Broders’/WHO grading system: over 90% of oral and oropharyngeal tumors are grade 2 [54].

However, results of a few previous studies have suggested that histological grading is a significant and independent predictor for cervical lymph node metastasis in head and neck SCC [13, 17, 74-76]. It was also reported that a higher degree of histopathological grading created at a higher risk for CLNM in SCC of oral cavity [13, 18-19]. In a series of 315 consecutive patients with primary OSCC, González-García et al. [18] found that 13.5% of the patients with poor-difference SCC developed CLNM, in comparison with 5.2% of patients with well-differentiated tumors.

However, one must consider that the influence of histological subtypes of OSCC to CLNM has not been reported in the literature, and more studies are needed.

**Pattern of tumor invasion**

To overcome some of the problems associated with the Broders’/WHO grading system, Jakobbson et al. [77] firstly introduced a multifactorial histological malignancy grading system, considering multiple features of both the tumor cells and the interface between the tumor cells and the host tissues. Subsequently, several modifications followed in order to search for a better histologic prognosticator of the outcome of patients with OSCC [49, 74, 78-82], Anneroth et al. [80] and Bryne et al. [81]. advocated a new grading system based on the pattern of tumor invasion (POI) from the deep tumor margin to surrounding connective tissues. This system includes four categories: grade 1 tumors have pushing borders with well-defined delineations; grade 2 tumors have advancing fronts with solid cords, bands, and strands; grade 3 groups or cords of infiltrating tumor islands, consisting of greater than 15 cells per island, are identified in the invasive border; grade 4 tumors have obvious tumor cell dissociation in small groups, less than 15 cells per island, at the inter-face of the main tumor and the surrounding tissue.

Several independent workers have found POI showing a better prognostic value than the conventional Broders’/WHO grading system in predicting nodal metastasis, local recurrence, and survival [53, 81-84]. For example, Brandwein-Gensler et al. [63] also demonstrated that POI was more significant than positive surgical margin in predicting local recurrence and overall survival in patients with OSCC. Based on a retrospective study of 129 patients with SCC in the oral cavity, Kurita et al. [13] also found that POI was correlated with CLNM; although, it was not a significant independent predictor for CLNM.

**Tumor satellites and Tumor satellite distance**

Tumor satellites are defined as separate islands of tumor cells of any size, with intervening normal tissue at the tumor and nontumor interface [63]. By the same rule, tumor satellite distance (TSD), which reflects the sprea-
The definition of perineural invasion is similarly to lymphovascular invasion which is considered presence of the tissue adjacent to the peri and/or intra-tumoral nerves involved by neoplastic cells. Several previous researchers [6, 8, 19, 37, 59, 83, 88] have recognized it as a valuable prognosticator for neck metastases.

Its correlation with contralateral metastases of oral carcinoma has been analyzed in a few studies [6, 8, 18]. For example, González-García et al. [18] reported perineural infiltration of the primary tumor of OSCC was highly predictive for CLNM, as was illustrated by the appearance of pathologic contralateral lymph neck nodes in 17.02% of patients with perineural infiltration, in comparison with only 4.1% of those patients without perineural involvement.

Muscular infiltration

Muscular infiltration is a factor that can be measured in an objective manner. It describes whether or not there is tumoral cells observed adjacent to either the surface or deep muscular tissue. It has been reported to be a reliable and sufficient predictive factor of lymph node metastasis [43, 89-90] although, a few reports described it as not being an important prognostic factor [67, 91-92]. Byers et al. [90] reported that the probability of occult metastasis increased if muscular invasion exceeded 4 mm. It was also found that muscular infiltration showed a higher probability of occult metastasis and lower disease-free survival when tumors located to tongue and floor of the mouth in the initial stages by Pimenta Amaral et al. [43]. However, there has been no correlation found between CLNM in oral carcinoma and muscular infiltration thus far.

Desmoplastic reaction and peritumoral inflammation

To the best of our knowledge, no report has considered the possible correlation between CLNM and desmoplastic reaction, but a few have reported that desmoplastic reaction and peritumoral inflammation are significant predictive factors of cervical metastasis [17, 43, 93]. González-García et al. [17] reported that peritumoral inflammation was statistically significant in relation to CLNM in a retrospective analytic study of 203 patients with SCC of the tongue. They offer a possible explanation for this association that a low host immunological response around the primary tumor could allow easier dissemination of cancer cells through lymphatic drainage.

The impact of clinical treatment

Neck dissection

To prevent CLNM in oral carcinoma, neck dissection has been given much attention by surgeons. Although the importance of treatment of the neck in patients with palpable or radiologic positive lymph nodes is beyond doubt, elective treatment of the clinically negative neck continues to generate controversy. To the best of our knowledge, no consensus has been achieved on the use of contralateral neck treatment in OSCC patients at early
stage. The central point is whether prophylactic neck dissection for contralateral clinical N0 should be performed.

Numerous retrospective studies have supported the role of elective neck dissection in contralateral N0 oral cavity SCC when patients present a high risk for later CLNM. Elective neck dissection of the contralateral neck in OSCC can safely be performed as neck dissection of regions I, II, III, and IV [94-96]. As a limited procedure, the neck dissection has few complications or long-lasting side effects, and offers the advantage of an accurate classification [97-98] and the status of contralateral lymph nodes, which is closely linked to adjuvant treatments. Therefore, neck dissection is not only a therapeutic procedure, but also a diagnostic one [21], and an elective contralateral neck treatment is generally recommended for initial treatment in certain patients with oral cavity SCC. It has been reported that isolated unilateral cervical dissection is predictive for CLNM, accounting for only 1.8% of the patients that primarily underwent bilateral neck dissection developed CLNM, in comparison with 7.4% of those patients undergoing unilateral neck dissection [18].

Several independent authorities suggest one should carefully consider performing elective contralateral neck dissection (cN0) for oral squamous cell carcinoma patients in some certain situations, as follows:

I: tumors arising in the base of tongue and the floor of the mouth [6-8, 21, 34];
II: tumors crossing the midline [6, 17-18, 29, 99];
III: advanced staging (cT3-4) [8, 11, 13, 15, 17-18, 29];
IV: primary tumor more than 3.75 mm thick [20];
V: multiple ipsilateral nodes involvement [8, 13, 21, 29].

In contrast, elective neck dissection for the contralateral N0 neck in early oral carcinoma is not supported by others. On the one hand, some authors in their studies detected a very low incidence of contralateral occult metastases in oral carcinoma, and there has not been an accurate marker that can predict the occurrence of bilateral or contralateral lymph node metastasis currently. Therefore, some surgeons advocate an observation-only policy for the contralateral neck [15]. On the other hand, bilateral neck dissection was not significantly associated with a decrease in contralateral metastasis [14, 17] and has not been shown to have an advantage in previous reports. For example, Lim et al found that the difference between the disease-free survival rates of 82% for the “observation” group and 68% for the elective neck dissection group was not statistically significant [15]. Lin et al. [28] also demonstrated that patients with buccal carcinoma after radical resection, ipsilateral neck radiation was adequate, since bilateral prophylactic neck treatment did not confer an added benefit.

In summary, surgeons should take into account the detailed and individual study of risks and potential benefits of elective neck treatment for contralateral N0 neck while considering a small percentage of patients with oral carcinoma that finally develop CLNM.

**Adjuvant radiotherapy**

It suggested that the adjuvant radiotherapy (aRT) of the neck was individualized, and prophylactic radiotherapy has been performed in a few cases with other high-risk factors [6]. A few institutions have reported that adjuvant radiotherapy associated with an increase of contralateral regional control for patients with SCC in oral cavity. For example, Koo et al. [29] detected that the contralateral regional control rate was 100% in patients who received adjuvant radiotherapy, comparing to 97% of those who did not receive adjuvant radiotherapy. However, it is considered that it inappropriate to compare the contralateral regional control rate between those patients who did receive adjuvant radiotherapy and those who did not. One possible reason may be the fact that the patients who received adjuvant radiotherapy were those who had an advanced staging disease or worse prognosis, which would correlate to a high incidence of the contralateral metastasis. We have summarized the indications for contralateral and local-regional adjuvant radiotherapy (Table 1).

**Other relevant factors**

**Time of initial diagnosis**

It is interesting that a few authorities have remarked that the time of initial diagnosis is correlated to CLNM. In a series of 315 consecutive patients, 23.8% of the patients who were diagnosed 12 or more months after the appearance of the primary tumor developed CLNM, in comparison to 2.45% of those patients who were diagnosed within the first year, and the relative risk represented 9.71 [18]. As a matter of fact, the time of initial diagnosis is strongly related to tumor progress and affects the later metastasis and survival.

**Local-regional recurrence**

Only a few institutions have demonstrated the significant relationship between local-regional recurrence and CLNM. Liao et al. detected that local recurrence was an independent risk factor for CLNM of patients with oral cavity SCC. They observed that CLNM occurred...
Table 1 Indications for local-regional and contralateral aRT

| Location of aRT     | Indications                                                                 |
|---------------------|-----------------------------------------------------------------------------|
| Local-regional aRT  | Advanced T classifications (pT3 or more) [17-19, 29, 100]                   |
|                     | A positive resection margin in the specimen or surgical-free margins less than 1 cm [17-19, 29, 100] |
|                     | Multiple pathologic lymph neck nodes (with 3 or more) [6, 17-19, 29, 71, 100] |
|                     | TSD>0.5 mm, lymph or blood vessel invasion and ECS [6, 17-19, 71, 100]       |
|                     | Tongue carcinoma with thickness more than 9.5 mm [24]                      |
| Contralateral aRT   | Tumors crossing the midline [28-29]                                         |
|                     | pT3 tumors or more [29]                                                     |
|                     | Positive contralateral neck affection [6, 17-18, 28]                        |
|                     | Multiple positive nodes on the homolateral side [29]                       |

pT3: pathologic T3.

more frequently in patients with local recurrence, revealing 18% in patients with local recurrence and 5% in those without [19].

Time of CLNM occurring and follow-up

Most studies corroborate that CLNM mainly happens within two years postoperatively [8-9, 13, 17-19, 101-105]. For example, González-García et al. [17] reported CLNM occurred within the first two years after surgery in 89.9% of the affected patients. A few institutions have reported the details of the time that CLNM usually occurring (Table 2).

| Author               | Mean | Median | Range |
|----------------------|------|--------|-------|
| Kowalski et al. [8]   | 7.5  | 5.6    | 2-26  |
| Kurita et al. [13]    | –    | 6      | 2-22  |
| González-García et al. [17] | 11.4 | –      | 3-27  |
| González-García et al. [18] | 12.52| –      | 3-49  |
| Liao et al. [19]      | 8.6  | 6      | 1-41  |

Due to the increased risk of CLNM within the first two years after surgery, special efforts should be made to detect early metastasis for SCC of the oral cavity, and close follow-up is mandatory during this period of time, lest the recurrence be beyond salvage [2, 5, 9, 13, 17-19, 102, 106-107]. Regular ultrasound and some other modern diagnostic modalities such as CT, MRI, PET, LS and USG-guided fine needle aspiration cytology, are worthy of consideration since they are more sensitive than clinical examination to detect occult nodal metastasis. Authors have given the regular frequencies of follow-up after surgery, as follows:

- first year: every month [14, 108];
- second year: every 2 months [14];
- third year: every 3 months [13-14];
- thereafter: biannually for life [13-14].

Conclusion

CLNM are not unusual in patients with OSCC, but it is an inarguable truth that patients presenting with CLNM in OSCC have a poor prognosis. At the same time, it is not practical or advisable to perform prophylactic neck dissection for contralateral clinical N0 in all patients with OSCC. Therefore, they should be carefully screened and clinical-histopathologic prognosticators must be globally considered for each individual case. It is important for clinicians to pay careful attention to prognostic variables of CLNM and adopt more aggressive prophylactic strategies, such as surgery and adjuvant treatment. However, we have obviously found that the UICC TNM classification is not suitable for predicting later metastasis, especially CLNM. A more comprehensive classification system is therefore necessary to guide clinically therapeutic strategies, particularly in the prediction of later cervical lymph node metastases. Some of well-established histological predictive factors should be included as part of this routine system, such as tumor thickness, histological grading, and ECS. We also found that the incidence and some related prognosticators of CLNM differ considerably among reports, diverse factors can be held responsible for such differences: inherent selection bias, problems in tumor staging, the lack of standard for clinical strategies, and pathological protocols. Therefore, exchange and cooperation among different centers should provide useful and reliable information in the future.

References

1. Shah JP, Candela FC, Poddar AK. The patterns of cervical lymph node metastases from squamous carcinoma of the
Clinical-histopathologic factors influencing CLNM in OSCC

1. Dias FL, Kligerman J, Matos de Sá G, et al. Elective neck dissection versus observation in stage I squamous cell carcinomas of the tongue and floor of the mouth. *Otolaryngol Head Neck Surg* 2001; 125: 23–29.

2. Shinohara S, Takada M, Sasai K, et al. Impact of lymph node metastasis on the pattern of failure and survival in oral carcinomas. *Am J Surg* 2003; 185: 278–284.

3. Greenberg JS, El Naggar AK, Mo V, et al. Disparity in pathologic and clinical lymph node staging in oral tongue carcinoma. *Cancer* 2003; 98: 508–515.

4. Capote A, Escorial V, Muñoz-Guerra MF, et al. Elective neck dissection in early-stage oral squamous cell carcinoma – does it influence recurrence and survival? *Head Neck* 2007; 29: 3–11.

5. Capote-Moreno A, Naval L, Muñoz-Guerra MF, et al. Prognostic factors influencing contralateral neck lymph node metastases in oral and oropharyngeal carcinoma. *J Oral Maxillofac Surg* 2010; 68: 268–275.

6. Feind CR, Cole RM. Contralateral spread of head and neck cancer. *Am J Surg* 1969; 118: 660–665.

7. Kowalski LP, Bagietto R, Lara JR, et al. Factors influencing contralateral lymph node metastasis from oral carcinoma. *Head Neck* 1999; 21: 104–110.

8. Fakhri AR, Rao RS, Borges AM, et al. Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. *Am J Surg* 1989; 158: 309–313.

9. Martin H, Del Valle B, Ehrlich H, et al. Neck dissection. *Cancer* 1951; 4: 441–499.

10. Woolgar JA. Histological distribution of cervical lymph node metastases from intraoral/oropharyngeal squamous cell carcinomas. *Br J Oral Maxillofac Surg* 1999; 37: 175–180.

11. Haddadin KJ, Sourat DS, Webster MH, et al. Natural history and patterns of recurrence of tongue tumours. *Br J Plast Surg* 2000; 53: 279–285.

12. Kurita H, Koike T, Narikawa JN, et al. Clinical predictors for contralateral neck lymph node metastasis from unilateral squamous cell carcinoma in the oral cavity. *Ocular Oncol* 2004; 40: 898–903.

13. Chow TL, Chow TK, Chan TT, et al. Contralateral neck recurrence of squamous cell carcinoma of oral cavity and oropharynx. *J Oral Maxillofac Surg* 2004; 62: 1225–1228.

14. Lim YC, Lee JS, Koo BS, et al. Treatment of contralateral N0 neck in early squamous cell carcinoma of the oral tongue: elective neck dissection versus observation. *Laryngoscope* 2006; 116: 461–465.

15. Zbiern P, Nuyens M, Caversaccio M, et al. Elective neck dissection for carcinomas of the oral cavity: occult metastases, neck recurrences, and adjuvant treatment of pathologically positive necks. *Am J Surg* 2006; 191: 756–760.

16. González-Garcia R, Naval-Gías L, Sastre-Pérez J, et al. Contralateral lymph neck node metastasis of primary squamous cell carcinoma of the tongue: a retrospective analytic study of 203 patients. *Int J Oral Maxillofac Surg* 2007; 36: 507–513.

17. González-Garcia R, Naval-Gías L, Rodríguez-Campo FJ, et al. Contralateral lymph neck node metastasis of squamous cell carcinoma of the oral cavity: a retrospective analytic study in 315 patients. *J Oral Maxillofac Surg* 2008; 66: 1390–1398.

18. Liao CT, Huang SF, Chen IH, et al. Risk stratification of patients with oral cavity squamous cell carcinoma and contralateral neck recurrence following radical surgery. *Ann Surg Oncol* 2009; 16: 159–170.

19. Bier-Laning CM, Durazo-Arvizu R, Muzzaffar K, et al. Primary tumor thickness as a risk factor for contralateral cervical metastases in T1/T2 oral tongue squamous cell carcinoma. *Laryngoscope* 2009; 119: 883–888.

20. Olszowy B, Tsalemchuk Y, Schotten KJ, et al. Frequency of bilateral cervical metastases in oropharyngeal squamous cell carcinoma: a retrospective analysis of 352 cases after bilateral neck dissection. *Head Neck* 2011; 33: 239–243.

21. Rassekh CH, Johnson JT, Myers EN. Accuracy of intraoperative staging of the N0 neck in squamous cell carcinoma. *Laryngoscope* 1995; 105: 1334–1336.

22. Nieuwenhuis EJ, Casteljns JA, Pijpers R, et al. Wait-and-see policy for the N0 neck in early oral and oropharyngeal squamous cell carcinoma using ultrasonography-guided cytology: is there a role for identification of the sentinel node? *Head Neck* 2002; 24: 282–289.

23. De Cicco C, Trifirò G, Calabrese L, et al. Lymphatic mapping to tailor selective lymphadenectomy in cN0 tongue carcinoma: beyond the sentinel node concept. *Eur J Nucl Med Mol Imaging* 2006; 33: 900–905.

24. Ng SH, Yen TC, Liao CT, et al. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. *J Nucl Med* 2005; 46: 1136–1143.

25. Mancuso AA. Cervical lymph node metastases: oncologic imaging and diagnosis. *Int J Radiat Oncol Biol Phys* 1984; 10: 411–423.

26. van den Brekel MW, Stel HV, Casteljns JA, et al. Cervical lymph node metastasis: assessment of radiologic criteria. *Radiology* 1990; 177: 379–384.

27. Lin CY, Lee LY, Huang SF, et al. Treatment outcome of combined modalities for buccal cancers: unilateral or bilateral neck irradiation? *Int J Radiat Oncol Biol Phys* 2008; 70: 1373–1381.

28. Koo BS, Lim YC, Lee JS, et al. Management of contralateral N0 neck in oral cavity squamous cell carcinoma. *Head Neck* 2006; 28: 896–901.

29. Spiro RH, Alfonso AE, Farr HW, et al. Cervical node metastasis from epidermoid carcinoma of the oral cavity and oropharynx: a critical assessment of current staging. *Am J
Evaluation of metastasis. Mohit Moore C, Kuhns JG, Greenberg RA. Thickness as prognostic factor to clinical stages I and II squamous cell carcinoma of the tongue cancer. González Kuroki oral tongue carcinoma. Kowalski LP, Santos CR, Magrin J, et al. Factors influencing contralateral metastasis and prognosis from pyriform sinus carcinoma. Maddox WA. Hayes Martin lecture. Vicissitudes of extended ‘commando’ operations for retromolar trigone carcinoma. Kowalski LP, Hashimoto I, Magrin J. End results of 114 extended “commando” operations for retromolar trigone carcinoma. Am J Surg 1993; 166: 374–379.

Califano L, Zuiri A, Mangone GM, et al. Surgical management of the neck in squamous cell carcinoma of the tongue. Br J Oral Maxillofac Surg 1999; 37: 320–323.

Maddox WA. Hayes Martin lecture. Vicissitudes of extended ‘commando’ operations for retromolar trigone carcinoma. Kowalski LP, Hashimoto I, Magrin J. End results of 114 extended “commando” operations for retromolar trigone carcinoma. Am J Surg 1993; 166: 374–379.

Califano L, Zuiri A, Mangone GM, et al. Surgical management of the neck in squamous cell carcinoma of the tongue. Br J Oral Maxillofac Surg 1999; 37: 320–323.

Maddox WA. Hayes Martin lecture. Vicissitudes of extended ‘commando’ operations for retromolar trigone carcinoma. Kowalski LP, Hashimoto I, Magrin J. End results of 114 extended “commando” operations for retromolar trigone carcinoma. Am J Surg 1993; 166: 374–379.

Califano L, Zuiri A, Mangone GM, et al. Surgical management of the neck in squamous cell carcinoma of the tongue. Br J Oral Maxillofac Surg 1999; 37: 320–323.
adequate margin of surgical resection in oral cancer? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 107: 625–629.

61 Batsakis JG. Surgical excision margins: a pathologist’s perspective. Adv Anat Pathol 1999; 6: 140–148.

62 Spiro RH, Guillamondegui O Jr, Paulino AF, et al. Pattern of invasion and margin assessment in patients with oral tongue cancer. Head Neck 1999; 21: 408–413.

63 Brandwein-Gensler M, Teixeira MS, Lewis CM, et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol 2005; 29: 167–178.

64 Yang TL, Wang CP, Ko JY, et al. Association of tumor satellite distance with prognosis and contralateral neck recurrence of tongue squamous cell carcinoma. Head Neck 2008; 30: 631–638.

65 Scholl P, Byers RM, Batsakis JG, et al. Microscopic cut-through of cancer in the surgical treatment of squamous carcinoma of the tongue. Prognostic and therapeutic implications. Am J Surg 1986; 152: 354–360.

66 Brennan JA, Mao L, Hruban RH, et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 1995; 332: 429–435.

67 Northrop M, Fletcher GH, Jesse RH, et al. Evolution of neck disease in patients with primary squamous cell carcinoma of the oral tongue, floor of mouth, and palate arch, and clinically positive neck nodes neither fixed nor bilateral. Cancer 1972; 29: 23–30.

68 Franchesci D, Gupta R, Spiro RH, et al. Improved survival in the treatment of squamous carcinoma of the oral tongue. Am J Surg 1993; 166: 360–365.

69 Myers JN, Greenberg JS, Mo V, et al. Extracapsular spread. A significant predictor of treatment failure in patients with squamous carcinoma of the tongue. Cancer 2001; 92: 3030–3036.

70 Woolgar JA, Rogers SN, Lowe D, et al. Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread. Oral Oncol 2003; 39: 130–137.

71 Greenberg JS, Fowler R, Gomez J, et al. Extent of extracapsular spread: a critical prognosticator in oral tongue cancer. Cancer 2003; 97: 1464–1470.

72 Petruzelli G. Patterns for neck recurrences. Oral Oncol 2005; 1: 37A.

73 Pindborg JJ, Reichart PA, Smith CJ, et al. World Health Organisation histological typing of cancer and pre-cancer of the oral mucosa. 2nd Edition. New York: Springer, 1997.

74 Yamamoto E, Miyakawa A, Kohama G. Mode of invasion and lymph node metastasis in squamous cell carcinoma of the oral cavity. Head Neck Surg 1984; 6: 938–947.

75 Magnano M, De Stefani A, Lerda W, et al. Prognostic factors of cervical lymph node metastasis in head and neck squamous cell carcinoma. Tumori 1997; 83: 922–926.

76 Magnano M, Bongioanimini G, Lerda W, et al. Lymphnode metastasis in head and neck squamous cells carcinoma: multivariate analysis of prognostic variables. J Exp Clin Cancer Res 1999; 18: 79–83.

77 Jakobsson PA, Eneroth CM, Killander D, et al. Histologic classification and grading of malignancy in carcinoma of the larynx. Acta Radiol Ther Phys Biol 1973; 12: 1–8.

78 Lund C, Sogoard H, Elbrond O, et al. Epidermoid carcinoma of the tongue. Histologic grading in the clinical evaluation. Acta Radiol Ther Phys Biol 1975; 14: 513–521.

79 Anneroth G, Hansen LS. A methodological study of histologic classification and grading of malignancy in oral squamous cell carcinoma. Scand J Dent Res 1984; 92: 448–468.

80 Anneroth G, Batsakis J, Luna M. Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas. Scand J Dent Res 1987; 95: 229–249.

81 Byrne M, Kopppang HS, Lilleng R, et al. New malignancy grading is a better prognostic indicator than Broders’ grading in oral squamous cell carcinomas. J Oral Pathol Med 1989; 18: 432–437.

82 Martinez-Gimeno C, Rodriguez EM, Vila CN, et al. Squamous cell carcinoma of the oral cavity: a clinicopathologic scoring system for evaluating risk of cervical lymph node metastasis. Laryngoscope 1995; 105: 728–733.

83 Woolgar JA, Scott J. Prediction of cervical lymph node metastasis in squamous cell carcinoma of the tongue/floor of mouth. Head Neck 1995; 17: 463–472.

84 Kurokawa H, Zhang M, Matsumoto S, et al. The high prognostic value of the histologic grade at the deep invasive front of tongue squamous cell carcinoma. J Oral Pathol Med 2005; 34: 329–333.

85 Sasaki A, Kai S, Iwashita Y, et al. Microsatellite distribution and indication for locoregional therapy in small hepato-cellular carcinoma. Cancer 2005; 103: 299–306.

86 Yuen PW, Lam KY, Chan AC, et al. Clinicopathological analysis of local spread of carcinoma of the tongue. Am J Surg 1998; 175: 242–244.

87 Kurita H, Uehara S, Funamoto S, et al. Intraoperative digital microscopic assessment of the deep surgical margins in oral carcinoma surgery: a preliminary report. Am J Surg 2006; 191: 84–88.

88 Brown B, Barnes L, Mazariegos J, et al. Prognostic factors in mobile tongue and floor of mouth carcinoma. Cancer 1989; 64: 1195–1202.

89 Ho CM, Lam KH, Wei W, et al. Occult lymph node metastasis in small oral tongue cancers. Head Neck 1992; 14: 359–363.

90 Byers RM, El-Naggar AK, Lee YY, et al. Can we detect or predict the presence of occult nodal metastases in patients
with squamous carcinoma of the oral tongue? *Head Neck* 1998; **20**: 138–144.

91 Jones KR, Lodge-Rigal D, Reddick RJ, *et al*. Prognostic factors in the recurrence of stage I and II squamous cell cancer of oral cavity. *Arch Otolaryngol Head Neck Surg* 1992; **118**: 483–485.

92 Morton RP, Ferguson CM, Lambie NK, *et al*. Tumor thickness in early tongue cancer. *Arch Otolaryngol Head Neck Surg* 1994; **120**: 717–720.

93 Lehn CN, Rapoport A. The desmoplasic lymph node reaction as a prognostic factor of cancer of the tongue and floor of the mouth. *Sao Paulo Med J* 1994; **112**: 591–596.

94 Shah JP. Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. *Am J Surg* 1990; **160**: 405–409.

95 Robbins KT. Indications for selective neck dissection: when, how, and why. *Oncology (Williston Park)* 2000; **14**: 1455–1464.

96 Lim YC, Koo BS, Lee JS, *et al*. Distributions of cervical lymph node metastases in oropharyngeal carcinoma: therapeutic implications for the N0 neck. *Laryngoscope* 2006; **116**: 1148–1152.

97 Ferlito A, Rinaldo A, Silver CE, *et al*. Elective and therapeutic selective neck dissection. *Oral Oncol* 2006; **42**: 14–25.

98 Wei WI, Ferlito A, Rinaldo A, *et al*. Management of the N0 neck—reference or preference. *Oral Oncol* 2006; **42**: 115–122.

99 Weber PC, Johnson JT, Myers EN. The impact of bilateral neck dissection on the pattern of recurrence and survival in supraglottic carcinoma. *Arch Otolaryngol Head Neck Surg* 1994; **120**: 703–706.

100 Jang WI, Wu HG, Park CI, *et al*. Treatment of patients with clinically lymph node-negative squamous cell carcinoma of the oral cavity. *Jpn J Clin Oncol* 2008; **38**: 395–401.

101 Vandebroucke C, Sancho-Garnier H, Chassagne D, *et al*. Elective versus therapeutic radical neck dissection in epidermoid carcinoma of the oral cavity: results of a randomized clinical trial. *Cancer* 1980; **46**: 386–390.

102 Snow GB, Annyas AA, van Slooten EA, *et al*. Prognostic factors of neck node metastasis. *Clin Otolaryngol Allied Sci* 1982; 7: 185–192.

103 Weiss MH, Harrison LB, Isaacs RS. Use of decision analysis in planning a management strategy for the stage N0 neck. *Arch Otolaryngol Head Neck Surg* 1994; **120**: 699–702.

104 Yuen AP, Lam KY, Chan AC, *et al*. Clinicopathological analysis of elective neck dissection for N0 neck of early oral tongue carcinoma. *Am J Surg* 1999; **177**: 90–92.

105 Hao SP, Tsang NM. The role of supraomohyoid neck dissection in patients of oral cavity carcinoma (small star, filled). *Oral Oncol* 2002; **38**: 309–312.

106 Kokermueller H, Brachvogel P, Eckardt A, *et al*. Neck dissection in oral cancer—clinical review and analysis of prognostic factors. *Int J Oral Maxillofac Surg* 2002; **31**: 608–614.

107 Kowalski LP. Results of salvage treatment of the neck in patients with oral cancer. *Arch Otolaryngol Head Neck Surg* 2002; **128**: 58–62.

108 Atula TS, Grénman R, Varpula MJ, *et al*. Palpation, ultrasound, and ultrasound-guided fine-needle aspiration cytology in the assessment of cervical lymph node status in head and neck cancer patients. *Head Neck* 1996; **18**: 545–551.